成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Medicinal Research Reviews >>article
Medicinal Research Reviews

Medicinal Research Reviews

IF: 10.9
Download PDF

Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs

Published:12 August 2018 DOI: 10.1002/med.21528 PMID: 30101496
Manoj Kumar Jaiswal

Abstract

Over the past decades, a multitude of experimental drugs have been shown to delay disease progression in preclinical animal models of amyotrophic lateral sclerosis (ALS) but failed to show efficacy in human clinical trials or are still waiting for approval under Phase I–III trials. Riluzole, a glutamatergic neurotransmission inhibitor, is the only drug approved by the USA Food and Drug Administration for ALS treatment with modest benefits on survival. Recently, an antioxidant drug, edaravone, developed by Mitsubishi Tanabe Pharma was found to be effective in halting ALS progression during early stages. The newly approved drug edaravone is a force multiplier for ALS treatment. This short report provides an overview of the two drugs that have been approved for ALS treatment and highlights an update on the timeline of drug development, how clinical trials were done, the outcome of these trials, primary endpoint, mechanism of actions, dosing information, administration, side effects, and storage procedures. Moreover, we also discussed the pressing issues and challenges of ALS clinical trials and drug developments as well as future outlook.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
5-Methyl-2-phenyl-1,2-dihydropyrazol-3-one 89-25-8 C10H10N2O 901 suppliers $6.00-$4424.01
Riluzole 1744-22-5 C8H5F3N2OS 427 suppliers $5.00-$1183.00

Similar articles

IF:2.2

Benzimidazole drugs and modulation of biotransformation enzymes

Research in veterinary science J Vel??k , V Baliharová ,etc Published: 1 April 2004
IF:4.8

Quetiapine Fumarate for the Treatment of Multiple Sclerosis: Focus on Myelin Repair

CNS Neuroscience & Therapeutics Simon Zhornitsky, Voon Wee Yong,etc Published: 22 July 2013